• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Intra-Cellular Therapies Inc.

    4/29/24 4:46:03 PM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ITCI alert in real time by email
    DEFA14A 1 d232805ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Under §240.14a-12

    Intra-Cellular Therapies, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     


    LOGO

    + MMMMMM C 1234567890 ENDORSEMENT_LINE______________ SACKPACK_____________ MR A SAMPLE Online DESIGNATION (IF ANY) ADD 1 Go to www.envisionreports.com/ITCI or scan 000001 ADD 2 the QR code — login details are located in the ADD 3 shaded bar below. ADD 4 MMMMMMMMM ADD 5 ADD 6 Stockholder Meeting Notice 1234 5678 9012 345 Important Notice Regarding the Availability of Proxy Materials for the Intra-Cellular Therapies, Inc. Annual Stockholder Meeting to be Held on June 14, 2024 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2024 notice and proxy statement and the 2023 annual report to stockholders are available at: www.envisionreports.com/ITCI Easy Online Access — View your proxy materials and vote. Step 1:o to www.envisionreports.com/ITCI Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before June 4, 2024 to facilitate timely delivery. 2NOT COY +


    LOGO

    Stockholder Meeting Notice The 2024 Annual Meeting of Stockholders of Intra-Cellular Therapies, Inc. will be held on June 14, 2024 at 11:00 A.M. Eastern Time, virtually via the internet at meetnow.global/MLNFN5Z. To access the virtual meeting, you must have the information that is printed in the shaded bar located on the reverse side of this form. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommends a vote FOR the nominee and FOR Proposals 2, 3 and 4. 1. Election of one director to serve a three-year term expiring in 2027. 2. To approve the amendment and restatement of the Company’s Amended and Restated 2018 Equity Incentive Plan. 3. To ratify of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. 4. To approve by an advisory vote the compensation of the Company’s named executive officers, as disclosed in the proxy statement. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.envisionreports.com/ITCI. Click Cast Your Vote or Request Materials. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to [email protected] with “Proxy Materials Intra-Cellular Therapies, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by June 4, 2024.

    Get the next $ITCI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ITCI

    DatePrice TargetRatingAnalyst
    2/24/2025$140.00 → $132.00Outperform → Neutral
    Mizuho
    1/31/2025$119.00 → $132.00Buy → Hold
    Canaccord Genuity
    9/6/2024$68.00 → $92.00Neutral → Overweight
    Piper Sandler
    1/3/2024$83.00Outperform
    Robert W. Baird
    12/11/2023$75.00Outperform
    TD Cowen
    4/20/2023$80.00Overweight
    Morgan Stanley
    8/22/2022$64.00 → $49.00Buy → Neutral
    Goldman
    7/7/2022$74.00Buy
    Mizuho
    More analyst ratings

    $ITCI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intra-Cellular Therapies downgraded by Mizuho with a new price target

    Mizuho downgraded Intra-Cellular Therapies from Outperform to Neutral and set a new price target of $132.00 from $140.00 previously

    2/24/25 7:10:56 AM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intra-Cellular Therapies downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Intra-Cellular Therapies from Buy to Hold and set a new price target of $132.00 from $119.00 previously

    1/31/25 7:02:57 AM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intra-Cellular Therapies upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Intra-Cellular Therapies from Neutral to Overweight and set a new price target of $92.00 from $68.00 previously

    9/6/24 7:44:31 AM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ITCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salas Eduardo Rene returned $206,844 worth of shares to the company (1,567 units at $132.00), closing all direct ownership in the company (SEC Form 4)

    4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)

    4/2/25 8:34:41 PM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Riggs Rory B returned $17,359,584 worth of shares to the company (131,512 units at $132.00), closing all direct ownership in the company (SEC Form 4)

    4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)

    4/2/25 5:47:21 PM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Halstead Michael returned $2,812,524 worth of shares to the company (21,307 units at $132.00), closing all direct ownership in the company (SEC Form 4)

    4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)

    4/2/25 5:46:14 PM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ITCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

    VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwindsStrategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026Management to host conference call today, May 1, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commerciali

    5/1/25 7:00:41 AM ET
    $ITCI
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

    Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same period in 2023 Full year 2024 CAPLYTA net product sales were $680.5 million, representing year-over-year growth of 47% The U.S. Food and Drug Administration (FDA) accepted for review the lumateperone supplemental New Drug Application (sNDA) submission for adjunctive treatment of major depressive disorder (MDD) BEDMINSTER, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial result

    2/21/25 8:00:48 AM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

    Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has potential to become a standard of care for most common depressive disorders CAPLYTA® adds to Johnson & Johnson's robust lineup of therapies with $5 billion+ potential in peak year salesi and further solidifies sales growth above analyst expectations now through the remainder of the decade Promising clinical-stage pipeline with best-in-disease potent

    1/13/25 6:32:27 AM ET
    $ITCI
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ITCI
    SEC Filings

    View All

    SEC Form 15-12G filed by Intra-Cellular Therapies Inc.

    15-12G - Intra-Cellular Therapies, Inc. (0001567514) (Filer)

    4/14/25 8:55:29 AM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Intra-Cellular Therapies Inc.

    EFFECT - Intra-Cellular Therapies, Inc. (0001567514) (Filer)

    4/10/25 12:15:05 AM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POSASR filed by Intra-Cellular Therapies Inc.

    POSASR - Intra-Cellular Therapies, Inc. (0001567514) (Filer)

    4/2/25 4:32:55 PM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ITCI
    Financials

    Live finance-specific insights

    View All

    Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

    VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwindsStrategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026Management to host conference call today, May 1, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commerciali

    5/1/25 7:00:41 AM ET
    $ITCI
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

    Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same period in 2023 Full year 2024 CAPLYTA net product sales were $680.5 million, representing year-over-year growth of 47% The U.S. Food and Drug Administration (FDA) accepted for review the lumateperone supplemental New Drug Application (sNDA) submission for adjunctive treatment of major depressive disorder (MDD) BEDMINSTER, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial result

    2/21/25 8:00:48 AM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

    Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has potential to become a standard of care for most common depressive disorders CAPLYTA® adds to Johnson & Johnson's robust lineup of therapies with $5 billion+ potential in peak year salesi and further solidifies sales growth above analyst expectations now through the remainder of the decade Promising clinical-stage pipeline with best-in-disease potent

    1/13/25 6:32:27 AM ET
    $ITCI
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ITCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Intra-Cellular Therapies Inc.

    SC 13G/A - Intra-Cellular Therapies, Inc. (0001567514) (Subject)

    11/12/24 10:32:13 AM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Intra-Cellular Therapies Inc.

    SC 13G - Intra-Cellular Therapies, Inc. (0001567514) (Subject)

    10/10/24 12:36:28 PM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Intra-Cellular Therapies Inc. (Amendment)

    SC 13G/A - Intra-Cellular Therapies, Inc. (0001567514) (Subject)

    2/13/24 5:08:02 PM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ITCI
    Leadership Updates

    Live Leadership Updates

    View All

    Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer

    NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sanjeev Narula will join the Company on August 12, 2024 and will serve as Executive Vice President, Chief Financial Officer. Mr. Narula will report to Dr. Sharon Mates, ITCI's Chairman and Chief Executive Officer. Lawrence Hineline, who currently serves as Chief Financial Officer, will retire on the same date but will continue to serve as a consultant to the Company for a period of time to ensure a smooth transition. "I am excited to welcome Mr.

    8/7/24 7:40:54 AM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors

    NEW YORK, April 21, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the appointment of E. Rene Salas to the Intra-Cellular Therapies Board of Directors. Mr. Salas will serve as a member of the audit committee. "We are pleased to welcome Rene Salas to the Intra-Cellular Therapies Board," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. "Rene's extensive financial and life sciences advisory experience will be very valuable as we continue to grow our business and pursue our mission to develop innova

    4/21/22 8:00:00 AM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cibus Appoints Co-Founder Rory Riggs, as Chief Executive Officer

    Cibus, a leading agricultural biotechnology company, announced today the appointment of Rory Riggs, co-founder, and Chairman of Cibus, to serve as Chief Executive Officer. He will succeed Peter Beetham, PhD, also a Cibus co-founder, who has been appointed President and Chief Operating Officer of the 20-year-old company. "Since our founding, Rory has been an important strategic partner in the success of Cibus and we are pleased that he is deepening his involvement in the company's growth as CEO," said Dr. Beetham. "With the recent progress toward a European approval of Cibus' proprietary precision gene-editing technology, as well as other recent Cibus commercial announcements, this manageme

    10/7/21 9:00:00 AM ET
    $FGEN
    $ITCI
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care